Horizon Scanning Roundtable: Where Could Amylin Biology Create Value Beyond Metabolic Disease?

• Investigating amylin's potential in type 1 diabetes for glycemic control and hypoglycemia reduction
• Examining metabolic benefits for MASH, kidney disease, and cardiovascular outcomes
• Discussing speculative but intriguing indications: addiction, alcohol use disorder, sleep disorders, and Alzheimer's disease

Speakers:

Brent Meadows

Chief Business Officer

Senovia Biosciences